139 related articles for article (PubMed ID: 28652780)
1. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.
Chang H; Kim JS; Choi YJ; Cho JG; Woo JS; Kim A; Kim JS; Kang EJ
Onco Targets Ther; 2017; 10():2983-2992. PubMed ID: 28652780
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 and PD-L2 Expression in Different Tumor Stages and Types of Malignant Salivary Gland Neoplasms: A Single-center Experience.
Leaf Flag B; Cam I; Civriz AH; Tunce EB; Ozcan BC; Akyol YK; Deger HM; Vural C; Ozturk M
Appl Immunohistochem Mol Morphol; 2024 Jun; ():. PubMed ID: 38847110
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.
Mosconi C; de Arruda JAA; de Farias ACR; Oliveira GAQ; de Paula HM; Fonseca FP; Mesquita RA; Silva TA; Mendonça EF; Batista AC
Oral Oncol; 2019 Jan; 88():95-101. PubMed ID: 30616805
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Witte HM; Gebauer N; Lappöhn D; Umathum VG; Riecke A; Arndt A; Steinestel K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260165
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in malignant salivary gland tumors.
Harada K; Ferdous T; Ueyama Y
BMC Cancer; 2018 Feb; 18(1):156. PubMed ID: 29409471
[TBL] [Abstract][Full Text] [Related]
7. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
Solinas C; Garaud S; De Silva P; Boisson A; Van den Eynden G; de Wind A; Risso P; Rodrigues Vitória J; Richard F; Migliori E; Noël G; Duvillier H; Craciun L; Veys I; Awada A; Detours V; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
Front Immunol; 2017; 8():1412. PubMed ID: 29163490
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms.
Tapias LF; Shih A; Mino-Kenudson M; Muniappan A; Gaissert HA; Lanuti M; Mathisen DJ; Ott HC
Eur J Cardiothorac Surg; 2019 Apr; 55(4):691-698. PubMed ID: 30418532
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
11. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.
Sridharan V; Gjini E; Liao X; Chau NG; Haddad RI; Severgnini M; Hammerman P; El-Naggar A; Freeman GJ; Hodi FS; Rodig SJ; Dranoff G; Schoenfeld JD
Cancer Immunol Res; 2016 Aug; 4(8):679-87. PubMed ID: 27312343
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
15. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
Ohtaki Y; Kaira K; Atsumi J; Nagashima T; Kawashima O; Ibe T; Kamiyoshihara M; Onozato R; Fujita A; Yazawa T; Sugano M; Iijima M; Nakazawa S; Obayashi K; Kosaka T; Yajima T; Kuwano H; Shirabe K; Mogi A; Shimizu K
Am J Transl Res; 2018; 10(10):3243-3253. PubMed ID: 30416665
[TBL] [Abstract][Full Text] [Related]
17. Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Miyake M; Oda Y; Nishimura N; Morizawa Y; Ohnishi S; Hatakeyama K; Fujii T; Hori S; Gotoh D; Nakai Y; Anai S; Torimoto K; Tsukamoto S; Fujii H; Kido A; Honoki K; Matsumura Y; Okajima E; Tanaka N; Fujimoto K
Oncol Lett; 2020 Nov; 20(5):190. PubMed ID: 32952659
[TBL] [Abstract][Full Text] [Related]
18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronan and CD44 expression in minor salivary gland tumors.
Xing R; Regezi JA; Stern M; Shuster S; Stern R
Oral Dis; 1998 Dec; 4(4):241-7. PubMed ID: 10200702
[TBL] [Abstract][Full Text] [Related]
20. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
Schwarz S; Ettl T; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Oral Oncol; 2008 Jun; 44(6):563-70. PubMed ID: 17936671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
